查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589264

囊肿纤维化市场：依药物类别、给药途径- 2025-2030 年全球预测

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

囊肿纤维化市场2023年估值为58.8亿美元，预计到2024年将达到64.4亿美元，复合年增长率为9.53%，预计到2030年将达到111.3亿美元。

囊肿纤维化(CF) 是一种影响呼吸和消化器官系统的遗传性疾病，CFTR 基因突变会导致产生黏稠的黏液。解决 CF 的必要性在于它对患者的生活品质和预期寿命产生深远影响，从而产生了对有效治疗的巨大需求。该市场主要针对为管理和治疗 CF 症状而开发的药品、诊断产品和医疗设备。最终使用者主要是需要对 CF 患者进行高级治疗方法的医院、诊所和专科医疗机构。影响 CF 市场的关键成长要素包括由于诊断技术的改进而导致盛行率增加、製药公司增加研发投资以及全球医疗基础设施的加强。创新基因疗法和个人化医疗方法的发展存在潜在的治疗机会，CRISPR和mRNA技术的突破正在为CF的标靶治疗铺平道路。公司可以透过投资与研究机构的伙伴关係关係并优先考虑个人化医疗解决方案来抓住这些机会。然而，治疗成本高、法律规范严格、新兴市场认知度低等限制因素为市场扩张带来了挑战。此外，CF 的遗传学很复杂，需要进行广泛的研究才能充分了解突变特异性治疗方法，这可能会减慢引入新治疗方法的速度。创新的最佳领域包括基因编辑技术的进步、药物传递系统的改进以及寻找罕见突变的新治疗方法。详细分析表明，在技术进步和对改进且易于使用的治疗方法的持续需求的推动下，市场竞争激烈但充满挑战。策略联盟、对前沿研究的持续投资以及提高全球知名度的努力对于利用市场机会和应对挑战至关重要。

主要市场统计
基准年[2023] 58.8亿美元
预测年份 [2024] 64.4亿美元
预测年份 [2030] 111.3亿美元
复合年增长率（%） 9.53%

市场动态：揭示快速发展的囊肿纤维化市场的关键市场洞察

供需的动态交互作用正在改变囊肿纤维化市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 囊肿纤维化盛行率增加和诊断技术的改进
    • 提高全球对囊肿纤维化的认识
    • 非政府组织、政府和私人公司的积极努力
  • 市场限制因素
    • 专利到期和学名药
    • 基因突变率增加
  • 市场机会
    • 研发活动和强大的药物开发平臺
    • 策略联盟、併购的增加
  • 市场问题
    • 治疗费用高、病理生理学复杂

波特的五力：驾驭囊肿纤维化市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解囊肿纤维化市场的外部影响

外部宏观环境因素在塑造囊肿纤维化市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解囊肿纤维化市场的竞争格局

对囊肿纤维化市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：囊肿纤维化市场供应商的绩效评估

FPNV定位矩阵是评估囊肿纤维化市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製囊肿纤维化市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对囊肿纤维化市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 囊肿纤维化盛行率的增加和诊断技术的改进
      • 提高全球对囊肿纤维化的认识
      • 非政府组织、政府和私人公司的积极倡议
    • 抑制因素
      • 专利到期和学名药
      • 基因突变率增加
    • 机会
      • 研发活动和强大的药物开发平臺
      • 扩大策略合作、併购
    • 任务
      • 治疗费用高且病理生理复杂
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章囊肿纤维化市场：依药物类别

  • 介绍
  • 支气管扩张剂
  • 囊肿纤维化治疗剂
  • 黏液溶解药物
  • 胰酵素补充品

第七章囊肿纤维化市场：依给药途径

  • 介绍
  • 吸入器
  • 口腔医学

第八章美洲囊肿纤维化市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太囊肿纤维化市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲囊肿纤维化市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alcresta Therapeutics, Inc.
  • AlgiPharma AS
  • AstraZeneca PLC
  • CHIESI Farmaceutici SpA
  • Elucigene Diagnostics by Delta Diagnostics (UK) Limited
  • F. Hoffmann-La Roche AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • NovaBIoTics Ltd.
  • Novartis AG
  • Pharmaxis Ltd.
  • PTC Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-4316E4E89581

The Cystic Fibrosis Market was valued at USD 5.88 billion in 2023, expected to reach USD 6.44 billion in 2024, and is projected to grow at a CAGR of 9.53%, to USD 11.13 billion by 2030.

Cystic Fibrosis (CF) is a genetic disorder that affects the respiratory and digestive systems, caused by mutations in the CFTR gene leading to the production of thick, sticky mucus. The necessity of addressing CF is underscored by its severe impact on patients' quality of life and life expectancy, creating a substantial demand for effective treatments. The market's application primarily lies within pharmaceuticals, diagnostics, and medical devices developed to manage and treat the symptoms of CF. End-use scopes are mainly hospitals, clinics, and specialty healthcare institutions that require advanced treatment options for CF patients. Key growth factors influencing the CF market include increasing prevalence due to improved diagnostic techniques, rising investments in research and development from pharmaceutical companies, and enhanced healthcare infrastructure globally. Potential opportunities lie in the development of innovative gene therapies and personalized medicine approaches, with breakthroughs in CRISPR and mRNA technology paving the way for targeted CF treatments. Companies can grab these opportunities by investing in partnerships with research institutions and prioritizing personalized healthcare solutions. However, limitations such as high treatment costs, stringent regulatory frameworks, and inadequate awareness in developing regions pose challenges to market expansion. The complexity of CF genetics also necessitates extensive research to fully comprehend mutation-specific therapies, potentially slowing the pace of new treatment introductions. Best areas for innovation include advancing gene editing technologies, improving drug delivery systems, and exploring novel therapeutics that address rare mutations. Detailed insights reveal a competitive yet rewarding market nature, driven by technological advances and a persistent demand for improved, accessible treatments. Strategic collaborations, continuous investment in cutting-edge research, and efforts to enhance global awareness are crucial for capitalizing on market opportunities and mitigating challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 5.88 billion
Estimated Year [2024] USD 6.44 billion
Forecast Year [2030] USD 11.13 billion
CAGR (%) 9.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cystic Fibrosis Market

The Cystic Fibrosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
    • Increasing global awareness for Cystic Fibrosis
    • Favorable initiatives are taken by NGOs, government, and private companies
  • Market Restraints
    • Expiring patents and generic drugs
    • Increase in genetic mutation rate
  • Market Opportunities
    • Research & development activities and robust drug development pipeline
    • Growing strategic collaborations, merger, and acquisition
  • Market Challenges
    • High cost involved in treatment and complicated pathophysiology

Porter's Five Forces: A Strategic Tool for Navigating the Cystic Fibrosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cystic Fibrosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cystic Fibrosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cystic Fibrosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cystic Fibrosis Market

A detailed market share analysis in the Cystic Fibrosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cystic Fibrosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cystic Fibrosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cystic Fibrosis Market

A strategic analysis of the Cystic Fibrosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cystic Fibrosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcresta Therapeutics, Inc., AlgiPharma AS, AstraZeneca PLC, CHIESI Farmaceutici S.p.A., Elucigene Diagnostics by Delta Diagnostics (UK) Limited, F. Hoffmann-La Roche AG, Galapagos NV, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., NovaBiotics Ltd., Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Bronchodilators, CFTR Modulators, Mucolytics, and Pancreatic Enzyme Supplements.
  • Based on Route of Administration, market is studied across Inhaled Drugs and Oral Drugs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
      • 5.1.1.2. Increasing global awareness for Cystic Fibrosis
      • 5.1.1.3. Favorable initiatives are taken by NGOs, government, and private companies
    • 5.1.2. Restraints
      • 5.1.2.1. Expiring patents and generic drugs
      • 5.1.2.2. Increase in genetic mutation rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Research & development activities and robust drug development pipeline
      • 5.1.3.2. Growing strategic collaborations, merger, and acquisition
    • 5.1.4. Challenges
      • 5.1.4.1. High cost involved in treatment and complicated pathophysiology
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cystic Fibrosis Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bronchodilators
  • 6.3. CFTR Modulators
  • 6.4. Mucolytics
  • 6.5. Pancreatic Enzyme Supplements

7. Cystic Fibrosis Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhaled Drugs
  • 7.3. Oral Drugs

8. Americas Cystic Fibrosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cystic Fibrosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cystic Fibrosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alcresta Therapeutics, Inc.
  • 3. AlgiPharma AS
  • 4. AstraZeneca PLC
  • 5. CHIESI Farmaceutici S.p.A.
  • 6. Elucigene Diagnostics by Delta Diagnostics (UK) Limited
  • 7. F. Hoffmann-La Roche AG
  • 8. Galapagos NV
  • 9. Gilead Sciences, Inc.
  • 10. Johnson & Johnson Services, Inc.
  • 11. NovaBiotics Ltd.
  • 12. Novartis AG
  • 13. Pharmaxis Ltd.
  • 14. PTC Therapeutics, Inc.
  • 15. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. CYSTIC FIBROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. CYSTIC FIBROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CYSTIC FIBROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CYSTIC FIBROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYME SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023